Eldon Mayer
About Eldon Mayer
Eldon Mayer is a seasoned biopharma executive with over 30 years of experience across various therapeutic areas, including oncology, and has held key roles in companies ranging from early-stage biotechs to large pharmaceutical firms.
Eldon Mayer Title and Role
Eldon Mayer currently holds the position of Chief Commercial Officer. In this role, he leverages his extensive experience in biopharma to drive commercial strategies and execution. His expertise spans early-stage biotech firms to full-scale pharmaceutical companies, focusing on commercializing therapeutic areas, especially oncology.
Eldon Mayer's Education and Expertise
Eldon Mayer boasts a robust educational background with a Bachelor of Science degree from Fairleigh Dickinson University and an MBA from Syracuse University. His expertise includes strategic planning, marketing, sales, market research/analytics, and finance, honed through years of experience in the biopharmaceutical industry.
Professional Background and Experience of Eldon Mayer
Eldon Mayer has accumulated over 30 years of experience in the biopharmaceutical industry. He has served in pivotal roles across various companies, including Schering-Plough, ALZA, Chiron, and Connetics. His career highlights include leading commercial teams and strategies, significantly impacting organizational growth and success.
Eldon Mayer’s Achievements in Biopharmaceuticals
During his tenure at Eiger Biopharmaceuticals, Eldon Mayer led the global launch of Zokinvy for progeria and progeroid laminopathies. At Rigel Pharmaceuticals, he built the commercial organization from scratch, successfully launching Tavalisse for chronic immune thrombocytopenia. While at Questcor Pharmaceuticals, he managed a commercial team that generated over $1 billion in annual sales of Acthar.
Board Memberships of Eldon Mayer
Eldon Mayer has served on the board of directors for several organizations, including Eiger BioPharmaceuticals, Promet Therapeutics, and the National Community Oncology Dispensing Association. His board memberships indicate a significant level of trust and recognition in the industry.